US Pharma MarketingMapLight to discuss future of autism drug with FDA despite Phase 2 disappointment
MapLight plans other meet with the FDA after its autism drug ML-004 missed its Phase 2 primary endpoint on social communication but improved irritability in teenagers. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and…
MapLight Therapeutics is holding to hope that there's a path forward for its autism drug despite the program flunking a mid-stage study.
The biotech’s treatment, known as ML-004, didn't meet the Phase 2 trial’s primary ...
Source: Endpoints News